Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHair loss after starting semaglutide is real, but it is not caused by the medicine itself. Several months in, some people notice more hair in the shower drain and jump to the obvious conclusion. The likely explanation is something called telogen effluvium — a temporary shedding triggered by rapid weight loss, not by semaglutide's chemistry. That distinction matters because it changes what happens next. These are prescription-only medicines and a prescriber assesses whether they are right for you before treatment begins, which is the right moment to raise any concern like this one.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you started semaglutide in the autumn, appetite dropped noticeably, and by late winter your clothes feel different and so does your hairbrush. The timing feels incriminating. Does taking semaglutide cause hair loss, or is something else going on?
The honest answer is both, partly. Hair follicles run on a growth cycle, and a significant physiological stressor (rapid weight reduction, eating considerably less, a major change in calorie intake) can push a large batch of hairs simultaneously into the resting phase. Two to four months later, those hairs shed. Doctors call this telogen effluvium. It is temporary, diffuse (spread across the scalp rather than patchy), and closely tied to the pace of weight change rather than to any specific medicine. The same pattern turns up after bariatric surgery, severe illness, or crash dieting.
Semaglutide does appear in the prescribing information with alopecia listed as an uncommon side effect, meaning it showed up in fewer than one in a hundred trial participants. Whether that reflects a direct pharmacological effect or simply the telogen effluvium accompanying rapid weight loss in those participants is not fully resolved. For a fuller picture of the side effects associated with semaglutide treatment, the NHS medicines information is a good starting point. What is clear is that the vast majority of people who notice shedding see it slow and then stop as their weight plateaus.
One reason hair responds badly to rapid weight loss is protein shortfall. Hair shaft is almost entirely keratin (a protein) and when overall intake drops sharply, the body prioritises vital organs. Hair follicles are not high on that list.
People on semaglutide often find their appetite falls substantially, which is the point, but eating far less without paying attention to what remains on the plate can mean protein intake slides. A rough target for adults trying to preserve lean mass during weight loss sits around 1.2–1.6 g of protein per kilogram of body weight, though your prescriber or a registered dietitian is the right person to set a personal figure. Practical strategies: prioritise protein at each meal before appetite signals stop you, choose high-satiety options like eggs, Greek yoghurt, fish, and legumes, and keep hydration up.
Iron and ferritin levels are worth mentioning to your GP too. Iron deficiency is common in people who eat less, and it is an independent cause of diffuse hair shedding that a simple blood test can identify. If payday falls on a Friday and you are planning a Monday order to make sure your treatment does not lapse, keep nutrition in mind over the gap, consistency matters for both weight and hair. Our Wegovy treatment information covers what to expect during the titration period.
Telogen effluvium is worth knowing about because it is common and self-limiting. It does not require stopping treatment. What does need prompt assessment is a different pattern: sudden or rapid loss, visibly thinning patches in one area, scalp redness or scaling, eyebrow or body hair loss alongside scalp shedding, or hair loss that continues for more than six months after weight has stabilised.
Those patterns point toward causes that need their own diagnosis, thyroid dysfunction, alopecia areata, iron deficiency anaemia, or other conditions that can coincide with starting any new treatment. Starting a weight-loss medicine does not cause those conditions, but the timing of starting treatment and noticing a symptom makes it easy to conflate them.
Contact your GP if hair loss fits any of the above descriptions. For general questions about how semaglutide fits your health picture, our support team can point you to the right resource, and our prescribers address side effects as part of every consultation. You can also report any suspected side effect directly to the MHRA via the Yellow Card scheme, that reporting genuinely helps regulators build a clearer picture of medicines in real-world use.
If you are still weighing up the full Wegovy side-effect profile before committing to treatment, that is a reasonable place to start. And for anyone wondering more broadly whether semaglutide-class medicines are associated with this kind of shedding, the Wegovy and hair loss page goes deeper on the clinical data, while our dedicated page on whether semaglutide causes hair loss looks specifically at the evidence behind that question. Our free consultation is where our prescribers discuss exactly these concerns before any prescription is written, and if you want a broader overview before that conversation, our guide to semaglutide peptide side effects covers the full range of what patients commonly report.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.